

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-13. (canceled)

14. (currently amended) A humanized immunoglobulin that specifically binds to human  $\gamma$ -IFN, which is a humanized version of the mouse AF2 immunoglobulin having a ~~mature~~ light chain variable region of SEQ ID No:2 and a ~~mature~~ heavy chain variable region of SEQ ID No:4, the humanized immunoglobulin comprising humanized heavy and light chains, provided that position 11 according to the Kabat numbering system of the humanized heavy chain variable region framework is occupied by the amino acid present in the equivalent position of the mouse AF2 heavy chain variable region framework.

15. (currently amended) A humanized immunoglobulin that specifically binds to human  $\gamma$ -IFN, which is a humanized version of the mouse AF2 immunoglobulin having a ~~mature~~ light chain variable region of SEQ ID No:2 and a ~~mature~~ heavy chain variable region of SEQ ID no:4, the humanized immunoglobulin comprising humanized heavy and light chains, provided that position 11 according to the Kabat numbering system of the humanized heavy chain variable region framework is substituted with the amino acid present in the equivalent position of the mouse AF2 heavy chain variable region framework.

16. (previously presented) The humanized immunoglobulin of claim 15 that specifically binds to human  $\gamma$ -IFN with an affinity constant within four-fold of the affinity of the mouse AF2 antibody.

17. (cancel)

18. (currently amended) The humanized immunoglobulin of any of claims 14, 15[[,]] or 16 ~~or~~ 17, comprising CDRs from the mouse AF2 immunoglobulin and heavy and light chain variable region frameworks (~~SEQ ID NOS: 13 and 12~~) from the human EU immunoglobulin (SEQ ID NOS: 13 and 12).

19. (previously presented) The humanized immunoglobulin of claim 18, further provided that position H38 according to the Kabat numbering system is occupied by the amino acid present in the equivalent position of the mouse AF2 heavy chain variable region framework.

20. (previously presented) The humanized immunoglobulin of claim 18, further provided that positions H11, H27, H28, H30, H38, H48, H67, H68, H70, H72, H74, H93, H95, H98, H107, H108, H109, H111 according to the Kabat numbering system are occupied by the amino acid present in the equivalent position of the mouse AF2 heavy chain, positions L48 and L70 according to the Kabat numbering system are occupied by the amino acid present in the equivalent position of the mouse AF2 light chain, and position L63 is occupied by the amino acid present in the equivalent position of a consensus sequence of light chains of human immunoglobulins.

21. (currently amended) The humanized immunoglobulin according to any of claims 14, 15 or 16 that comprises two light chain/heavy chain dimers.

22. (currently amended) The humanized immunoglobulin of any of claims 14, 15 or 16 that is of IgG1 isotype.

23. (currently amended) The humanized immunoglobulin according to any of claims 14, 15 or 16 which is purified to at least 95% homogeneity.

24. (currently amended) A humanized mature heavy chain comprising a variable region having a sequence designated SEQ ID NO:10.

25. (currently amended) A humanized immunoglobulin comprising a mature heavy chain variable region of SEQ ID NO:8 and a mature light chain variable region of SEQ ID NO:6, wherein the humanized immunoglobulin, which is more than ~~at least~~ 80% pure by weight.

26. (previously presented) A humanized immunoglobulin comprising a mature heavy chain variable region of SEQ ID NO:8 and a mature light chain variable region of SEQ ID NO:6, wherein the humanized immunoglobulin has isotype selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.